Diagnostics

OraSure Technologies appointed Steven K. Boyd to its Board as a Class II director and named Jack Kenny as Board Chair, succeeding Mara Aspinall. The board now has seven directors, six independent, with three new independent directors added in the past three years. These changes aim to drive profitable growth, innovation, and shareholder value, building on a strengthened balance sheet and improved profitability by focusing on diagnostics and sample management. Boyd’s experience in healthcare investment and Kenny’s diagnostics background are expected to contribute to the company’s strategic direction.

Waters Corporation and BD (Becton, Dickinson and Company) have announced a definitive agreement to merge BD’s Biosciences & Diagnostic Solutions business with Waters, creating a leading life science and diagnostics company. The deal, valued at $17.5 billion structured as a Reverse Morris Trust, is expected to double Waters’ addressable market to $40 billion and generate $345 million in annualized EBITDA synergies by 2030.The combined company anticipates approximately $6.5 billion in 2025 sales and mid-teens adjusted EPS growth over five years, with the transaction boosting adjusted EPS within the first year.

Seer and Korea University are collaborating on a large-scale study to discover early cancer biomarkers using Seer’s Proteograph ONE Assay and mass spectrometry. This initiative aims to analyze 20,000 plasma samples to identify novel blood-based biomarkers for improved cancer diagnostics, particularly for young adults. The study, supported by the K-Health MIRAE initiative, utilizes AI-driven analytics, promising accelerated analysis, reduced costs, and the potential for earlier cancer detection and improved patient outcomes.